Overall, ICI first-line therapy is unhelpful compared to EGFR TKI monotherapy, especially given the outstanding safety profile of the third-generation EGFR TKI osimertinib for advanced EGFRm NSCLC patients with PFS reported at 18.9 months and OS reported at 38.6 months in the FLAURA trial (23). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.